IFNA1, interferon alpha 1, 3439

N. diseases: 662; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection. 30614547 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma. 31019054 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα. 30723923 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 AlteredExpression disease BEFREE Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo. 31201869 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR. 31446638 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE In this study, 74 patients with chronic HBV infection who had virological responses to 180 μg/week Peg-IFNα-2a treatment were included; 38 (20 and 18 HBeAg positive and negative, respectively) of these patients were treated with 245 mg/day TDF, and 36 (20 and 16 HBeAg positive and negative, respectively) were treated with 0.5 mg/day ETV upon relapse after initial treatment discontinuation. 30963812 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Mice incapable of downregulating the IFN receptor and Ch25h were resistant to TEV uptake, TEV-induced pre-metastatic niche, and melanoma lung metastases; however, ablation of Ch25h reversed these phenotypes. 30645975 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE A unique case of NMOSD caused by IFN-α therapy in malignant melanoma is presented. 31030016 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. 31014399 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Treating with anti-HN neutralizing mAb induced significant decline in the cytotoxicity of IFN R<sup>-/-</sup> NK cells toward Hepa1-6 cell line (P < 0.05). 31120191 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Compared with IFN-only regimen, no significant increase in HCC risk was found for use of DAA-only (HR, 1.53; 95% CI, 0.73-3.23), DAA + IFN (HR, 1.02; 95% CI, 0.51-2.06), or any-DAA (HR, 1.04; 95% CI, 0.65-1.65). 31451519 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE PD-L1 positive HCC was observed in 6 cases of the IFN group and 4 cases of the DAA group. 31423211 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE We further found that RIP3 knockdown results in an increase of MDSCs and a decrease of interferon gamma-positive (IFN-γ<sup>+</sup> ) cluster of differentiation 8-positive (CD8<sup>+</sup> ) tumor-infiltrating lymphocytes (IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells) in hepatoma tissues, thus promoting immune escape and HCC growth in immunocompetent mice. 31021443 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma. 31019054 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE With CTLA-4 Nb16 stimulation, dendritic cell/hepatocellular carcinoma fusion cells (DC/HepG2-FCs) enhanced autologous CD8<sup>+</sup> T cell proliferation and production of IFN-<i>γ</i><i>in vitro</i>, thereby leading to enhanced killing of tumor cells. 31847937 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Only APRI was associated with HCC recurrence; and post-IFN AFP and HCC recurrence were predictive of subsequent mortality independently. 30527565 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Type I IFN (IFN-I) therapy is an important therapeutic option for HBV patients. 30150992 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. 30537741 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients. 30133478 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-α in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-α against HBV.(Hepatology 2018;67:1237-1252). 29059468 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment. 29791282 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 AlteredExpression disease BEFREE The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification. 29079518 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL). 28635613 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM. 29901821 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.400 Biomarker disease BEFREE Among children with hepatitis B envelope antigen-positive genotype C chronic HBV infection, we compared the efficacy of combination therapy with nucleotide analogues and IFN-α in 11 children with 12 historical cases treated with IFN monotherapy. 29981262 2018